Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 27Neoplasm Metastasis 16Skin Neoplasms 12Breast Neoplasms 9Multiple Myeloma 8Kidney Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hematologic Neoplasms 7Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 6Uterine Cervical Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Carcinoma, Non-Small-Cell Lung 5Urogenital Neoplasms 4Stomach Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Vaginal Neoplasms 2Rectal Neoplasms 2

Interventions

Specimen Handling 17Magnetic Resonance Spectroscopy 15Gemcitabine 13Cisplatin 8Biopsy 8Radiotherapy 7Mitomycin 6Cystoscopy 6pembrolizumab 5Trastuzumab 5Paclitaxel 5Fluorouracil 5cabozantinib 4atezolizumab 4Radiation 4erdafitinib 3dehydroftorafur 3Transurethral Resection of Bladder 3Sunitinib 3Sorafenib 3Platinum 3Nivolumab 3Mitozytrex 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3valrubicin 2tipifarnib 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urinary Bladder Neoplasms × fludarabine × Clear all
NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡